Sackler Family Wins Immunity From Opioid Lawsuits

Image caption,

State and local governments say OxyContin triggered an opioid epidemic

The billionaire owners of Purdue Pharma will be protected from lawsuits linked to the US opioid crisis in exchange for a $6bn (£4.85bn) settlement.

Purdue, which filed for bankruptcy in 2019 amid thousands of lawsuits, made drugs like OxyContin and is blamed for fuelling the crisis.

On Tuesday, an appeals court ruled that its owners, the Sackler family, would receive full immunity from civil suits.

In exchange, they will pay $6bn to help address opioid addiction.

The family have long demanded civil immunity, and the court's ruling removes a key barrier to the money being paid out. It will go to local and state governments, as well as individuals who sued the company, and is expected to fund rehabilitation programmes and other addiction treatments.

A three-judge panel of the US Court of Appeals for the Second Circuit issued the ruling. The details of the settlement have been contested in the courts for several years.

Judge Eunice Lee said the claims filed against Purdue Pharma were inextricably linked to the Sackler family. She ruled that if lawsuits were permitted to continue targeting them, Purdue Pharma would not be able to reach a bankruptcy deal.

The ruling paves the way for the settlement which must now receive final approval from a court. While it protects the family from any future civil cases, it does not protect them from potential criminal charges.

As a part of the settlement the Sackler family will give up ownership of the company, which will be rebranded as Knoa, and send its profits to a fund to help treat addiction.

The family has been made to listen to stories of those impacted by the drug as part of the deal. Many of the complainants were state and local governments who alleged OxyContin triggered an opioid epidemic.

The family will also allow their name to be removed from buildings and scholarships.

Media caption,

The heroin-ravaged city fighting back

In 2021, there were more than 100,000 overdose deaths in the US, with opioids involved in 75% of those according to the US Centres for Disease Control and Prevention.

Purdue Pharma promoted opioids as non-addictive painkillers, and the company has previously pleaded guilty to charges relating to its opioid marketing. The Sackler family has denied wrongdoing.

The families of now-deceased Mortimer and Raymond Sackler, the two founders of Purdue Pharma, welcomed Tuesday's decision.

"The Sackler families believe the long-awaited implementation of this resolution is critical to providing substantial resources for people and communities in need," they said in a statement.

Purdue Pharma said they would focus on investing money into "victim compensation, opioid crisis abatement and overdose rescue medicines" going forward.

RECENT NEWS

From Chip War To Cloud War: The Next Frontier In Global Tech Competition

The global chip war, characterized by intense competition among nations and corporations for supremacy in semiconductor ... Read more

The High Stakes Of Tech Regulation: Security Risks And Market Dynamics

The influence of tech giants in the global economy continues to grow, raising crucial questions about how to balance sec... Read more

The Tyranny Of Instagram Interiors: Why It's Time To Break Free From Algorithm-Driven Aesthetics

Instagram has become a dominant force in shaping interior design trends, offering a seemingly endless stream of inspirat... Read more

The Data Crunch In AI: Strategies For Sustainability

Exploring solutions to the imminent exhaustion of internet data for AI training.As the artificial intelligence (AI) indu... Read more

Google Abandons Four-Year Effort To Remove Cookies From Chrome Browser

After four years of dedicated effort, Google has decided to abandon its plan to remove third-party cookies from its Chro... Read more

LinkedIn Embraces AI And Gamification To Drive User Engagement And Revenue

In an effort to tackle slowing revenue growth and enhance user engagement, LinkedIn is turning to artificial intelligenc... Read more